Autolus appoints former BioNTech CSO Ryan Richardson to Board

Autolus Therapeutics plc

Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).
Will receive £33,000 annual retainer and initial option grant for 80,000 ADSs at $1.41/ADS, vesting over 36 months.
Richardson led BioNTech's corporate strategy, capital markets, and multiple M&A deals.
Prior roles include Executive Director at J.P. Morgan Healthcare Investment Banking (2011–2018).

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.